-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Once-daily medications for the pharmacological management of ADHD in adults
Review
(2231) Views (660) Full article downloads
Authors: Oleg v Tcheremissine, Lori M Lieving
Published Date May 2009
Volume 2009:5 Pages 367 - 369
DOI: http://dx.doi.org/10.2147/TCRM.S4206
Oleg v Tcheremissine1, Lori M Lieving2
1Department of Psychiatry, Behavioral Health Center – Carolinas Medical Center, Charlotte, NC, USA; 2Carolinas College of Health Sciences, Charlotte, NC, USA
Abstract: Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment option for ADHD across all age groups. The current review’s goals are (a) to critically examine the current state of knowledge regarding once-daily formulations of pharmacotherapies for treatment of adults with ADHD and (b) to provide clinicians with evidence-based information regarding the safety, efficacy and tolerability of once-daily medications for adult ADHD. The reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line therapeutic option for the treatment of adults with ADHD. The once-daily pharmacological agents are effective therapeutic options for the treatment of adults with ADHD. In the US, based on the available evidence, once-daily medications are currently underutilized in adults with ADHD compared to pediatric population.
Keywords: adults, attention deficit/hyperactivity disorder, once-daily pharmacotherapies
Readers of this article also read:
The benefits and risks of testosterone replacement therapy: a review
Finasteride in the treatment of patients with benign prostatic hyperplasia: a review
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient onsiderations and the role of lisdexamfetamine
Cancer prevention, aerobic capacity, and physical functioning in survivors related to physical activity: a recent review
Development and implementation of an online hybrid model for teaching evidence-based practice to health professions: processes and outcomes from an Australian experience
The economic impact of obesity in the United States
Effect of HIV infection on time to recovery from an acute manic episode
The effect of aging, nutrition, and exercise during HIV infection
Interprofessional education: a concept analysis
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




